Compare Crispr Therapeutics AG (CRSP) vs iShares Bitcoin Trust (IBIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares Bitcoin Trust — how do they compare? Crispr Therapeutics AG trades at $50.95 (market cap $5.06B), while iShares Bitcoin Trust trades at $46.78 (market cap $68.92B). The key difference: iShares Bitcoin Trust is far larger — about 13.6× Crispr Therapeutics AG's market cap, and iShares Bitcoin Trust is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and iShares Bitcoin Trust for 40 Days on average.
| CRSP | IBIT | |
|---|---|---|
Market Cap | $5.06B | $68.92B |
Volume | 1,678,371 | 46,059,179 |
Sector | Health | Crypto-linked |
52-Week High | $74.92 | $68.74 |
52-Week Low | $44.34 | $33.29 |
Typical Hold Time | 77 Days | 40 Days |
Enterprise Value | $3.48B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 6.59% over 24 hours amid bearish technical signals. The company shows negative profitability metrics with -4,101.26% net income margin and -$581.60M net loss for 2025, though Q2 2026 EPS beat expectations. Recent news highlights upcoming clinical data presentations and commercial progress with CASGEVY gene therapy. Cash flow remains negative from operations but positive overall due to financing activities.
While analyst consensus remains bullish with 57.9% buy ratings and $67.83 price target, significant execution risks persist. The stock faces pressure from sustained cash burn and competitive threats, but potential catalysts include upcoming clinical data readouts and CASGEVY revenue growth. Investors should weigh high-risk biotech volatility against breakthrough therapy potential.
IBIT trades at $47.21, down 2.64% on the day, with technical indicators showing a bullish overall signal driven by moving averages. The stock faces immediate support at $46 and resistance at $48. Recent news highlights strong institutional interest with BlackRock's IBIT recording $196 million in daily inflows on October 1, 2026, signaling renewed investor confidence in Bitcoin-focused investment products.
The outlook remains cautiously optimistic given institutional inflows and technical strength, though the absence of traditional financial metrics like P/E and P/S limits fundamental analysis. Key risks include market volatility and regulatory uncertainty, while analyst sentiment appears mixed with technical indicators favoring bullish momentum near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →
